CHANTAL BAPTISTE: Open Payments
NPI 1851867766 · CLERMONT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,472 in 249 payments from 19 companies in 2025. Trend: 2023 $4,513 · 2024 $4,245 · 2025 $5,472
Food & beverage: $5,472
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 40 | $956 |
| Teva Pharmaceuticals USA, Inc. | 43 | $554 |
| Otsuka America Pharmaceutical, Inc. | 16 | $470 |
| Alkermes, Inc. | 15 | $347 |
| Axsome Therapeutics, Inc. | 9 | $337 |
| Vanda Pharmaceuticals Inc. | 13 | $329 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $326 |
| Janssen Pharmaceuticals, Inc | 17 | $323 |
| Medtronic, Inc. | 3 | $305 |
| E.R. Squibb & Sons, L.L.C. | 16 | $284 |
Products named: INGREZZA, REXULTI, Auvelity, CAPLYTA, SYMPLICITY G3, INVEGA SUSTENNA, COBENFY, VRAYLAR.
Industry payments across FL — which companies pay providers there.
